Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frailty-stratified frontline therapy trial in transplant-ineligible newly diagnosed multiple myeloma
ACTRN12619001199101Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing Velcade + lenalidomide + dexamethasone, Velcade + dexamethasone and lenalidomide + dexamethasone (3 arms). Primary endpoints: Overall response rate and Deliverability-limiting toxicity. Started Dec 2019; status: active, not recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12619001199101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001199101.